EU approves expanded use of ABBV's Rinvoq and AZN's Imfinzi and Enhertu. NVS set to invest $23B to boost U.S. manufacturing.

Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis.